Skip to content

A Clinical Study on the Combined Use of Moxa Needle Therapy and Blood-Letting Therapy for Post-Bell's Palsy Sequelae of Blood Stasis Type

A Clinical Study on the Combined Use of Moxa Needle Therapy and Blood-Letting Therapy for Post-Bell's Palsy Sequelae of Blood Stasis Type

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002197
Enrollment
Unknown
Registered
2025-11-17
Start date
2025-04-15
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post sequelae of Bell's palsy

Interventions

1:Conventional Western medicine treatment + facial minute fire needle therapy + bloodletting therapy by puncturing blood vessels
2:Standard Western medicine treatment + conventional acupuncture

Sponsors

Yunnan University of Traditional Chinese Medicine Second Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meets the above Chinese medicine diagnostic criteria and is diagnosed as blood stasis type; (2) Meets the above Western medicine diagnostic criteria; (3) Patient age is between 16 and 70 years old; (4) Disease duration is =90 days; (5) Has not participated in other clinical studies and guarantees not to participate in other clinical studies during this research period; (6) The subject voluntarily participates in the experiment, agrees to, and signs the informed consent form (see Appendix Five). Note: Only those who meet all six criteria above can be included in this study.

Exclusion criteria

Exclusion criteria: (1) Patients who do not meet the aforementioned diagnostic criteria and inclusion criteria; (2) Patients with facial paralysis secondary to other diseases, such as acute infectious polyneuritis (GBS), Lyme disease, mumps or parotid tumors, otitis media, leprosy, post-auricular suppurative lymphadenitis, posterior fossa lesions, cerebrovascular diseases, diabetic neuropathy, etc., or patients with severe primary diseases of the cardiovascular, hepatic, renal, or hematopoietic systems, or mental illness; (3) Patients with symptoms of Hunt's facial paralysis triad, or those with facial paralysis due to trauma or tumors, or central facial paralysis; (4) Patients with facial manifestations of synkinesis (synchronous movement of mouth and eyes), facial muscle inversion, or facial muscle spasms; (5) Patients with advanced malignant tumors, severe coronary artery disease, cardiac function grade III or above, end-stage uremia, cirrhosis, or other conditions of physical debilitation, or unstable vital signs; (6) Patients with aphasia, deafness, or severe cognitive impairment that prevents normal communication; (7) Patients with contraindications to acupuncture who are not suitable for acupuncture treatment; (8) Patients currently participating in other clinical trials. Note: Any patient meeting any of the above criteria should be excluded.

Design outcomes

Primary

MeasureTime frame
House-Brakmann Facial Nerve Function Grading;Facial Injury Severity Assessment;Neuroelectrophysiological examination;

Secondary

MeasureTime frame
Infrared thermography detection;

Countries

China

Contacts

Public ContactShi Tian Ai

Yunnan University of Traditional Chinese Medicine Second Affiliated Hospital

1914637181@qq.com15084839770

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026